Furthermore, treating HCC cells with protein synthesis inhibitor CHX and proteasome inhibitor MG132 showed that alterations in SLC7A11‐AS1 expression did not affect the synthesis or degradation of the SLC7A11 protein (Figure S6D,E). Here, SLC7A11 is linked to hepatocellular carcinoma.